Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
215 hedge funds and large institutions have $2.07B invested in Revance Therapeutics, Inc. in 2023 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 86 increasing their positions, 60 reducing their positions, and 39 closing their positions.
80% more call options, than puts
Call options by funds: $36.5M | Put options by funds: $20.2M
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
43% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 60
0% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 39
0% less funds holding
Funds holding: 216 → 215 (-1)
16% less capital invested
Capital invested by funds: $2.46B → $2.07B (-$389M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$47.6M |
| 2 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$38.2M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$31.7M |
| 4 |
DM
Deerfield Management
New York
|
+$27.1M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$21.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JCAM
Jericho Capital Asset Management
New York
|
-$46.3M |
| 2 |
Two Sigma Investments
New York
|
-$17.4M |
| 3 |
Capital World Investors
Los Angeles,
California
|
-$15.6M |
| 4 |
JP Morgan Chase
New York
|
-$14.6M |
| 5 |
Two Sigma Advisers
New York
|
-$13.3M |
RVNC Hedge Fund Activity: Q2 2023 in Review
215 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q2 2023, worth a combined $2.07B — down 16% from $2.46B a quarter earlier.
Fund positioning in RVNC was balanced in Q2 2023: 39 funds opened new positions, 39 closed out, 86 added to existing stakes and 60 trimmed.
The largest buyer was Invesco, adding an estimated $47.6M. The largest seller was Jericho Capital Asset Management, exiting entirely with an estimated $46.3M sold.
- 215 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q2 2023, down from 216 in Q1 2023.
- Funds reported $2.07B of Revance Therapeutics, Inc. stock for Q2 2023, down 16% quarter-over-quarter.
- 39 funds opened new Revance Therapeutics, Inc. positions in Q2 2023 and 39 closed out, a net change of 0 holders.
- The largest Revance Therapeutics, Inc. buyer in Q2 2023 was Invesco, an estimated $47.6M added.
- The largest Revance Therapeutics, Inc. seller in Q2 2023 was Jericho Capital Asset Management, an estimated $46.3M sold.
Based on aggregated 13F filings for Q2 2023.